
China Pharma Holdings, Inc.
CPHIAMEXHealthcareDrug Manufacturers - Specialty & Generic
前收盤價
US$0.98
−US$0.08 · -7.55%
CPHI公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Sell
Trim exposure — unfavorable risk-reward
估值
27
Expensive
動能
24
Weakening
情緒
52
Mixed
風險韌性
27
High Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
- 產業
- Drug Manufacturers - Specialty & Generic
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Zhilin Li
- 上市以來
- 2002年4月17日
- 僱員
- 215
市場位置
日內區間
目前US$0.98,
52週區間
目前US$0.98,
- 開盤價
- US$1.031
- 前收盤價
- US$1.06
- 成交量
- 27.54萬
- 0.06× 平均值
- 平均成交量
- 444.28萬
- 日均成交量
- 市值
- 3971.16萬 USD
- 貝塔
- 1.07
- 市場參考 1
- 50天平均值
- US$1.1114
- 低於平均水平-11.82%
- 200天平均值
- US$1.0096
- 低於平均水平-2.93%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 873.42萬 USD
- EV/EBITDA
- -5.8×
- 盈餘收益率
- -61.39%
- 自由現金流收益率
- 0.21%
獲利能力和效率
- 股東權益報酬率
- -14.02%
- 資產報酬率
- -10.28%
- 投入資本報酬率
- -11.28%
財務健康
- 流動比率
- 0.32×
- 奧特曼 Z 分數
- 0.85
- 皮奧特羅斯基 F 分數
- 2 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 414.43萬 USD | 452.89萬 USD | 701.13萬 USD | 810.41萬 USD | 964.19萬 USD |
| 銷貨成本 | 427.62萬 USD | 651.46萬 USD | 729.24萬 USD | 859.8萬 USD | 929.27萬 USD |
| 毛利 | −13.2萬 USD | −198.56萬 USD | −28.11萬 USD | −49.39萬 USD | 34.93萬 USD |
| 研究與開發 | 28.09萬 USD | 28.39萬 USD | 24.01萬 USD | 18.59萬 USD | 31.9萬 USD |
| 銷售、一般及管理費用 | 282.72萬 USD | 231.36萬 USD | 224.64萬 USD | 296.31萬 USD | 314.6萬 USD |
| 營業費用 | 295.66萬 USD | 260.32萬 USD | 247.07萬 USD | 305.51萬 USD | 320.98萬 USD |
| 利息收入 | 2003 USD | 6641 USD | 6602 USD | 1.08萬 USD | 3035 USD |
| 利息支出 | 10.2萬 USD | 15.41萬 USD | 33.36萬 USD | 43.46萬 USD | 54.2萬 USD |
| 折舊和攤銷 | 157.92萬 USD | 261.81萬 USD | 275.37萬 USD | 270.05萬 USD | 308.78萬 USD |
| 營業利益 | −308.85萬 USD | −458.89萬 USD | −275.18萬 USD | −354.9萬 USD | −286.05萬 USD |
| 淨利 | −318.76萬 USD | −473.64萬 USD | −307.88萬 USD | −397.28萬 USD | −339.95萬 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- 最新每股收益結果
- -0.04
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
CPHI 訊息
繼續GoAI的研究
在 GoAI 中研究CPHIresearch.disclaimer



